Wednesday, May 27, 2015

Tuesday Features

Profound Medical seeking CE Mark for TULSA-PRO this year

Profound Medical seeking CE Mark for TULSA-PRO this year

Profound Medical, which is going public next week, figures that data from a 30-patient safety and feasibility study of its transurethral ultrasound ablation (TULSA) technology for minimally invasive treatment of prostrate cancer will be sufficient to file for CE Mark approval in Europe before the end of 2015. Steven Plymale “We hope to launch TULSA-PRO... [Read more of this feature]


Provectus taking novel path to treat cancer

Provectus taking novel path to treat cancer

Rather than taking a biochemistry approach to develop drugs that kill cancer cells, Provectus Biopharmaceuticals (NYSE MKT:PVCT) is using physical chemistry by harnessing the unique properties of Rose Bengal, a first-in-class halogenated xanthene. Peter Culpepper “We are taking a different type of molecule and a different basis for the mechanism of... [Read more of this feature]


T2 Biosystems to double sales force this year

T2 Biosystems to double sales force this year

T2 Biosystems (NASDAQ:TTOO), which entered 2015 with seven direct sales reps, plans to add another eight during the year as it continues to roll out its first products: the T2Candida panel and T2Dx instrument for the detection of Candida fungal infections that cause sepsis. John McDonough “Our focus is on closing 30 accounts this year within the top... [Read more of this feature]


More Posts From Tuesday Features

Briefs

HCW starts Heat Biologics at buy

HCW starts Heat Biologics at buy

H.C. Wainwright has initiated coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and a 12-month target price of $13, based on a risk-adjusted revenues and earnings per share multiples valuation methodology. The stock closed at $6.43 on Monday. Heat’s biotechnology franchise is focused around allogeneic, off-the-shelf immunotherapies... [Read more of this brief]


Mira IV gets clearance for merger with Profound Medical

Mira IV gets clearance for merger with Profound Medical

Mira IV Acquisition (TSX-V:MRY.P) has received conditional acceptance from the TSX Venture Exchange for its qualifying transaction with closely-held Profound Medical. In accordance with the previously announced amalgamation agreement, Mira IV Subco, a wholly-owned subsidiary of Mira IV, will amalgamate with Profound. The transaction is expected to close... [Read more of this brief]


ROTH starts Vascular Biogenics at buy

ROTH starts Vascular Biogenics at buy

ROTH Capital Partners has initiated coverage of Vascular Biogenics (NASDAQ:VBLT) with a “buy” rating and a $13 price target. The stock closed at $5.05 on Thursday. Vascular has two technology platforms targeting oncology and immunology indications. The first platform is Vascular Targeting System (VTS), which is a multi-component gene therapy design... [Read more of this brief]


Amarantus in capital restructuring to up-list shares

Amarantus in capital restructuring to up-list shares

Amarantus BioSciences Holdings (OTCQB:AMBS) has implemented a 1-for-150 reverse stock split of its common stock to facilitate listing its shares on a national exchange this year. Trading on a split-adjusted basis will occur on final approval from the Financial Industry Regulatory Authority (FINRA). Following FINRA approval, the company’s common... [Read more of this brief]


Response Biomedical promotes COO Kinnaird to CEO

Response Biomedical promotes COO Kinnaird to CEO

Response Biomedical (OTCBB:RPBIF; TSX:RBM) has promoted COO, Dr. Barbara Kinnaird, to the position of CEO, effective immediately, succeeding interim CEO, Dr. Anthony Holler. Barbara Kinnaird, Ph.D. “Since her promotion to COO in September 2014, Dr. Kinnaird has successfully led Response through a series of strategic moves to position the company... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+